BACKGROUND: In recent years it has been supposed that impaired intestinal permeability represents an early event preceding the onset of inflammatory bowel disease (IBD). Since zonulin has been proposed as a biomarker of intestinal permeability, we investigated its role in patients with IBD and the correlation between serum and fecal zonulin. METHODS: A total of 118 IBD patients (86 Crohn's disease [CD] and 32 ulcerative colitis [UC]) and 23 healthy controls (HC) were prospectively enrolled. A serum sample was collected for all the subjects included in the study. A stool specimen collected in the same day of blood drawing was available for a subgroup of 33 IBD patients. Serum and fecal zonulin were tested by ELISA. Non-parametric statistical tests were used for data analysis. RESULTS: Serum zonulin concentration was higher in IBD patients compared to HC (34.5 [26.5-43.9] ng/mL vs. 8.6 [6.5-12.0] ng/mL, P<0.001) showing an area under the curve of 0.98 for their discrimination. No difference in serum zonulin concentration was observed between patients with CD and those with UC (P=0.074). An inverse correlation was observed between serum zonulin concentration and disease duration (rs=-0.30, P=0.001); no correlation was observed between serum and fecal zonulin (rs=0.15, P=0.394). CONCLUSIONS: Serum zonulin is highly sensitive for the evaluation of intestinal permeability in IBD patients. There is no correlation between zonulin values in serum and feces.
BACKGROUND: In recent years it has been supposed that impaired intestinal permeability represents an early event preceding the onset of inflammatory bowel disease (IBD). Since zonulin has been proposed as a biomarker of intestinal permeability, we investigated its role in patients with IBD and the correlation between serum and fecal zonulin. METHODS: A total of 118 IBDpatients (86 Crohn's disease [CD] and 32 ulcerative colitis [UC]) and 23 healthy controls (HC) were prospectively enrolled. A serum sample was collected for all the subjects included in the study. A stool specimen collected in the same day of blood drawing was available for a subgroup of 33 IBDpatients. Serum and fecal zonulin were tested by ELISA. Non-parametric statistical tests were used for data analysis. RESULTS: Serum zonulin concentration was higher in IBDpatients compared to HC (34.5 [26.5-43.9] ng/mL vs. 8.6 [6.5-12.0] ng/mL, P<0.001) showing an area under the curve of 0.98 for their discrimination. No difference in serum zonulin concentration was observed between patients with CD and those with UC (P=0.074). An inverse correlation was observed between serum zonulin concentration and disease duration (rs=-0.30, P=0.001); no correlation was observed between serum and fecal zonulin (rs=0.15, P=0.394). CONCLUSIONS: Serum zonulin is highly sensitive for the evaluation of intestinal permeability in IBDpatients. There is no correlation between zonulin values in serum and feces.
Authors: Gian Paolo Caviglia; Alessandra Tucci; Rinaldo Pellicano; Sharmila Fagoonee; Chiara Rosso; Maria Lorena Abate; Antonella Olivero; Angelo Armandi; Ester Vanni; Giorgio Maria Saracco; Elisabetta Bugianesi; Marco Astegiano; Davide Giuseppe Ribaldone Journal: J Clin Med Date: 2020-07-23 Impact factor: 4.241
Authors: Gian Paolo Caviglia; Chiara Rosso; Francesco Stalla; Martina Rizzo; Alessandro Massano; Maria Lorena Abate; Antonella Olivero; Angelo Armandi; Ester Vanni; Ramy Younes; Sharmila Fagoonee; Rinaldo Pellicano; Marco Astegiano; Giorgio Maria Saracco; Elisabetta Bugianesi; Davide Giuseppe Ribaldone Journal: J Clin Med Date: 2020-03-15 Impact factor: 4.241
Authors: Charlotte Skinner; Alex J Thompson; Mark R Thursz; Julian R Marchesi; Nikhil Vergis Journal: Therap Adv Gastroenterol Date: 2020-10-16 Impact factor: 4.409